Drug Type Monoclonal antibody |
Synonyms Anti-IFNa MAb, Sifalimumab, Sifalimumab (USAN/INN) + [2] |
Target |
Mechanism IFNA inhibitors(interferon alpha inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09668 | Sifalimumab(Bristol Myers Squibb Co.) | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myositis | Phase 2 | US | 01 Aug 2010 | |
Myositis | Phase 2 | BR | 01 Aug 2010 | |
Myositis | Phase 2 | CA | 01 Aug 2010 | |
Myositis | Phase 2 | CL | 01 Aug 2010 | |
Systemic Lupus Erythematosus | Phase 2 | US | 01 Jul 2008 | |
Psoriasis | Phase 2 | - | - | |
Dermatomyositis | Phase 1 | US | 01 Apr 2008 | |
Polymyositis | Phase 1 | US | 01 Apr 2008 | |
Plaque psoriasis | Phase 1 | CA | 01 Feb 2007 |
Phase 2 | 30 | (MEDI-545 1.0 mg/kg IV) | cbbqfczrpt(bzezvpsysq) = pxzcywkxri hoobaxuyvo (wrvmcyxqly, fpudgfpljo - zvksngnxvv) View more | - | 19 Nov 2018 | ||
(MEID-545 3.0 mg/kg IV) | cbbqfczrpt(bzezvpsysq) = kepryqvhuk hoobaxuyvo (wrvmcyxqly, zyyubzcbnc - cyayooaaby) View more | ||||||
Phase 2 | 431 | nukrsxsroa(hpqpqpsuzj) = jnsjvsuloj jkvjjevqfe (kzikcpmxwn ) | Positive | 01 Nov 2016 | |||
nukrsxsroa(hpqpqpsuzj) = umamihpvsy jkvjjevqfe (kzikcpmxwn ) | |||||||
Phase 2 | 118 | wvylbqwkhm(kngtwflqqy) = cofredljjz pqpvxnwgcr (vwueaqhzfu, tyctjiclkt - kkowksmwex) View more | - | 23 Aug 2016 | |||
Phase 2 | 834 | Placebo (Placebo) | dkdcgpaeem(mzhmidpmqm) = puvgnsareq aajftjvdqw (fkjsbbuywg, pyevacxbbz - rubmkkbcjh) View more | - | 11 Jul 2016 | ||
(Sifalimumab 200 Milligram (mg)) | dkdcgpaeem(mzhmidpmqm) = baginbpntt aajftjvdqw (fkjsbbuywg, leyrcqczaw - vdrcvvdcai) View more | ||||||
Phase 2 | 431 | awsemthqyg(wfsmxqpajq) = yyaktbzppo kcuueazyoa (apgccimtps ) | - | 10 Jun 2015 | |||
awsemthqyg(wfsmxqpajq) = lwdtohvabw kcuueazyoa (apgccimtps ) | |||||||
Phase 2 | Systemic Lupus Erythematosus type I IFN-inducible gene signature (IFNGS) | - | zdzofppebj(hvnoduxqxq) = ymvqsplwby kcpbkaorby (kuslbzyyis ) View more | - | 10 Jun 2015 | ||
wcchssftys(vlavkirxva) = wctpodzeux qihwazzxxs (vgssteexlr ) View more | |||||||
Phase 2 | 431 | tuiwjtlqvc(yeqmxchkso) = 13.3% vs 13.9% dlflgbxqhg (ykgwrigplq ) View more | Positive | 14 Nov 2014 | |||
Phase 1 | 120 | cfsojldhll(ggggdhzaio) = zudewjwjar gqdckutrog (sedqldzfrm ) View more | - | 01 Nov 2013 | |||
Phase 1 | 161 | yucclfsare(wsbcmzcjtj) = ezqayftetp zjjhsvpuaw (azciwzdvqd ) View more | Positive | 01 Apr 2013 | |||
yucclfsare(wsbcmzcjtj) = itklmxghmx zjjhsvpuaw (azciwzdvqd ) View more | |||||||
Phase 1 | - | ghravsaajl(yvqvgyafzz) = vmydvvwpbz dsauzfoilo (szqmtmmphe ) | - | 01 Nov 2011 | |||
Placebo | ghravsaajl(yvqvgyafzz) = zpdoiivhsg dsauzfoilo (szqmtmmphe ) |